GlobeNewswire·Nov 8, 2026, 5:34 PM ET

IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses

IMP761 demonstrated statistically significant, exposure-dependent inhibition of T-cell-driven immune responses in healthy volunteers
The drug was well tolerated across seven dose levels with no serious or severe adverse events reported
Pharmacokinetic data supports a four-week dosing interval for the ongoing multiple ascending dose portion of the study
The Phase I study utilizes a keyhole limpet haemocyanin challenge model to assess the ability to dampen strong tissue T-cell responses
Pre-clinical studies showed statistically significant reductions in T-cell activation & proliferation using samples from rheumatoid arthritis patients
Analysis of the multiple ascending dose portion is ongoing with no new safety signals observed to date
Results from the multiple ascending dose portion are anticipated in H1 CY2027 to inform dose selection for a potential Phase II program
IMP761 is a first-in-class LAG-3 agonist antibody designed to suppress pathogenic T-cell responses in autoimmune diseases
Immutep states IMP761 is the only LAG-3 agonist antibody currently in clinical development